Develops psychedelic medicine programs for mental health disorders, focusing on novel approaches to drug development and therapy.
MyMD Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is a clinical development stage pharmaceutical company dedicated to advancing therapeutic platforms aimed at addressing the root causes of various diseases. Established in 2014, MyMD Pharmaceuticals is focused on pioneering innovative treatments that target chronic inflammation and other pro-inflammatory cytokines through its lead drug platform, MYMD-1. This clinical stage small molecule not only regulates the immune system to control TNF-a but also holds promise in potentially delaying aging, extending longevity, and treating autoimmune diseases and COVID-19-associated depression.
In addition to MYMD-1, MyMD Pharmaceuticals is developing Supera-CBD, a synthetic derivative of cannabidiol designed to combat chronic pain, addiction, and epilepsy. This innovative approach underscores the company's commitment to leveraging cutting-edge research and development to provide therapeutic solutions that improve patient outcomes across diverse medical conditions.
Driven by a vision to transform healthcare through groundbreaking science, MyMD Pharmaceuticals continues to expand its portfolio and explore new avenues in therapeutic innovation. With a strategic focus on addressing unmet medical needs, the company remains poised to make significant strides in advancing novel treatments that positively impact global health.